GlassScriptPhysician profile
Yelda Nouri
NPI 1073803557
$19,958.23
in general payments reported to CMS, 2019-2025
20 companies · $7,651 in 2025
The $7,651 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,364 · 2020: $2,296 · 2021: $1,568 · 2022: $1,251 · 2023: $1,398 · 2024: $4,430 · 2025: $7,651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,199.75 |
| Food and Beverage | $279.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $7,918.28 | 2022-2025 | Datroway |
| Astrazeneca Pharmaceuticals LP | $5,013.93 | 2021-2025 | Enhertu |
| Puma Biotechnology, INC. | $2,100.85 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $1,700.00 | 2024 | |
| Pfizer INC. | $1,260.00 | 2021 | |
| Athenex Pharmaceutical Division, LLC | $1,250.00 | 2020 | |
| Kite Pharma, INC. | $140.87 | 2020-2021 | |
| Genzyme Corporation | $116.81 | 2019-2025 | |
| Janssen Research & Development, LLC | $95.25 | 2025 | |
| Genentech USA, INC. | $94.02 | 2019 | |
| Geron Corporation | $69.75 | 2025 | Rytelo |
| Tactile Systems Technology INC | $41.96 | 2021-2023 | Flexitouch Plus, Entre Plus |
| Merck Sharp & Dohme LLC | $39.74 | 2019 | |
| Shionogi INC | $28.76 | 2019 | |
| Seagen INC. | $18.00 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Secura Bio, INC. | $16.61 | 2021 | |
| Kyowa Kirin, INC. | $15.83 | 2019 | |
| Medtronic, INC. | $13.86 | 2023 | Propel |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yelda Nouri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.